Claims

1. A method for producing a cell aggregate comprising a ciliary marginal zone-like structure, comprising a step of culturing a cell aggregate comprising a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more and 100% or less of the tissue in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway and a substance inhibiting the FGF signal pathway for only a period before the appearance of a RPE65 gene-expressing cell, followed by culturing the resulting "cell aggregate in which a RPE65 gene-expressing cell does not appear" in a serum-free medium or serum-containing medium each free of a substance acting on the Wnt signal pathway.

2. The production method according to claim 1, wherein the cell aggregate in which a RPE65 gene-expressing cell does not appear is a cell aggregate in which Chx10 positive cells are present in the retinal tissue in a proportion of within 30% to 0% of the tissue.

3. The production method according to claim 1 or 2, wherein the resulting "cell aggregate in which a RPE65 gene-expressing cell does not appear" is cultured in a serum-free medium or serum-containing medium each free of a substance acting on the Wnt signal pathway until the proportion of Chx10 positive cells present in the retinal tissue reaches 30% or more of the tissue.

4. The production method according to any one of claims 1 to 3, wherein the retinal tissue is derived from a human pluripotent stem cell.

5. A reagent for evaluating toxicity or drug efficacy, the reagent comprising a cultured cell aggregate comprising a ciliary marginal zone-like structure produced by the production

method according to any one of claims 1 to 4.

6. A method for evaluating toxicity or drug efficacy of a test substance, comprising contacting the substance with a cultured cell aggregate comprising a ciliary marginal zone-like structure produced by the production method according to any one of claims 1 to 4, and assaying an influence of the substance on the ciliary marginal zone-like structure or the aggregate.

7. A cultured cell aggregate comprising a ciliary marginal zone-like structure produced by the production method according to any one of claims 1 to 4, for use as a biological material for transplantation.

8. A cultured cell aggregate comprising a ciliary marginal zone-like structure produced by the production method according to any one of claims 1 to 4, for use for the treatment of a disease due to a disorder of the ciliary marginal zone-like structure.

9. A cultured cell aggregate comprising a ciliary marginal zone-like structure produced by the production menthod according to any one of claims 1 to 4.